. .

BioChancePLUS

( )
relevant organisationTypeFields of acitivityFocusbased inManagementwas foundet inAddressEmailHomepageProfileContactNumber of employeesCertificatesBioChancePlusBioProfileScientific Advisory Board
DR. PETRY genmedics GMBHBiotechDevelopment, Medicine, NutrigenomicsStaphylococcus researchReutlingenJustus Dehnen (CEO)
Dr. Jörg Petry (CFO)
Dr. Bernhard Krismer (CSO)
Dr. Günther Thumm (COO)
Ferdinand-Lassalle-Strasse 57
72770 Reutlingen
Germany
Tel.: +49 (0)7121-95890
Fax: +49 (0)7121-958933
info@genmedics.comwww.genmedics.comDR. PETRY genmedics GmbH focuses on research into the Staphylococcus organism. The biotechnology firm, which has bases in Reutlingen and Tübingen, is not only seeking to combat the disease pathogen but also use it as a carrier agent for various active agents.

The pathogen Staphylococcus epidermidis is capable of forming a biofilm on a range of surfaces. Thanks to its high levels of resistance to a wide range of antibiotics, pathogenic Staphylococci are becoming a major hazard in the field of medicine in the context of biofilm-related, foreign-body infections. It is for this area of activity that DR. PETRY genmedics offers an evaluation of materials for biofilm formation. As a result, new medical materials such as foreign-body implants can be checked for their biofilm formation properties.

In addition to working with pathogenic Staphylococci, the firm also focuses on the expression of therapeutically-effective proteins in the food-grade bacterium S. carnosus.
Dr. Jörg PetryOptimisation of the expression and purification of two staphylolytic active agentsAssociated project NAPRAS; Development of new agents against biofilm formation on regenerative and synthetic tissue implants; Subproject 2: Assay development, screening, verificationProf. Friedrich Götz
Prof. Günther Jung P
Prof. Joachim-Volker Höltje
Prof. Rolf G. Werner
NMI Natural and Medical Sciences InstituteInstituteServicesTransfer of research results to industry, Transfer of research findings to the business sectorReutlingenProf. Dr. Hugo Hämmerle (Managing Director)
Dr. Alfred Stett (Deputy Managing Director), Prof. Dr. Hugo Hämmerle (Director)
Dr. Alfons Stett (Deputy Director)
1985Markwiesenstr. 55
D-72770 Reutlingen
Tel.: +49 (0)7121-515300
Fax: +49 (0)7121-5153016
, Markwiesenstrasse 55
72770 Reutlingen
Germany
Tel.: +49 (0)7121-515300
Fax: +49 (0)7121-5153016
info@nmi.de, info@nmi.dewww.nmi.de, www.nmi.deThe NMI was founded in 1985 as a non-profit foundation under civil law. The foundation comprises 12 mostly small- to medium-sized companies as well as the city of Reutlingen. A board of trustees, which is made up of representatives from research and industry, the Ministry of Economic Affairs and the Ministry of Science, Research and the Arts (Baden-Württemberg), oversees the institution. The NMI’s objective is the successful transfer of research findings to the world of business.
The NMI covers the following core areas of activity: pharmaceutical and biotechnology research, biomedical technology and surface technology. The scientists who work within the NMI’s 16 research groups are among the pioneers of groundbreaking technologies and are internationally renowned for their innovations and patents. It was here, for example, that micro-electrode arrays (MEAs) were developed. These arrays are used to determine the effects of substances on cardiac muscle and nerve cells. The system was further developed by MCS Multi Channel Systems in Reutlingen and is now marketed worldwide. In conjunction with industrial partners and publicly-funded research institutions, the NMI is also involved in the development of tests based on protein or peptide arrays. In future, these systems will play an important role in diagnostics. By miniaturising and parallelising test systems (microarray technology), numerous parameters can be determined simultaneously in the smallest sample volumes. The use of protein arrays increases the speed of tests and results in a dramatic reduction in the cost of diagnostics, as it is possible to analyse several hundred parameters in a single experiment. Working with other companies, the NMI also initiates projects for the optimisation and further development of implants and surgical instruments. These consortia enable small- and medium-sized companies to take part in research projects under the Institute’s guidance, without having to provide the necessary equipment or scientific expertise themselves. They can access the NMI’s technologies, systems and services, including equipment such as the “Focused Ion Beam”, which enables material samples in the nanometer range to be mapped and prepared. With this latest advancement of the scanning ion microscope, companies from the fields of medical technology and the automotive industry are investigating functional flaws in semiconductor chips, the failure of coatings or instances of corrosion damage. The NMI also operates a comprehensive database (www.biochipnet.com) that is available for biotechnology companies, research institutions and service providers free of charge., NMI was founded in 1985 as a non-profit-making foundation under civil law. The foundation includes 12 mostly small to medium-sized companies and the City of Reutlingen. A board of trustees, which is made up of representatives from research and industry, the Ministry of Economic Affairs and the Ministry of Science and Research (Baden-Württemberg), oversees the institution. The NMI’s objective is to successfully transfer research findings to the world of business.
The NMI is an established figure in its core areas of activity, namely: pharmaceuticals and biotechnology, biomedical technology and surface technology. The scientists, who work within the NMI in 13 working groups, are among the pioneers of groundbreaking technologies and are renowned internationally for their innovations and patents. It was here, for example, that micro-electrode arrays (MEAs) were developed. These are used to determine the effects of substances on cardiac muscle and nerve cells. The system was developed further by MCS Multi Channel Systems in Reutlingen and is marketed worldwide. In conjunction with industrial partners and publicly-funded research institutions, the NMI is also involved in the development of tests based on protein or peptide arrays. These systems will in future play an important role in diagnostics. By miniaturising and parallelising testing systems (micro-array technology), a range of measuring parameters can be determined simultaneously in even the smallest sample volumes. The use of protein arrays increases the speed of tests and results in a dramatic reduction in costs for diagnostics, since several hundred measuring parameters can be captured in a single experiment. Working with other companies, NMI also initiates projects for the optimisation and further development of implants and surgical instruments. These consortia enable small and medium-sized companies, under the Institute’s guidance, to take part in research projects without having to come up with the necessary equipment or scientific expertise themselves. They can access the NMI’s technologies, systems and services, such as the “Focused Ion Beam”, which enables material samples in the nanometer range to be mapped and prepared. With this latest further development of the scanning ion microscope, companies from the fields of medical technology and the automotive industry are investigating functional flaws in semiconductor chips, the failure of coatings or instances of corrosion damage. The firm also operates a comprehensive and freely-accessible BioChip database (www.biochipnet.com) for biotechnology companies, research institutions and service providers.
Dr. Nadja Gugeler – Public Relations (gugeler@nmi.de), Dr. Nadja Gugeler - Marketing (gugeler@nmi.de)ca. 130, Approx. 100Postgenomic Screening Platform – modular technology platform for complex biological assays – in conjunction with EDI and accelab GmbHJoint research project: Bio-reabsorbable collagen fibres for nerve regeneration.
Joint research project: Bio-artificial surface substitute for the treatment of degenerative cartilage diseases; subproject 3
M-fold Biotech GmbHBiotechServices, Development, ProteomicsStructural analyses, in vitro bonding and functional testing of membrane proteins, production of antibodiesTübingenDr. Hans Kiefer, Scientific Director
Dr. Wolfgang Vogt, Managing Director
1999Vor dem Kreuzberg 17
72070 Tübingen
Germany
Tel.: +49 (0)7071-7945-0
Fax: +49 (0)7071-7945-11
contact@m-phasys.comwww.m-phasys.comM-fold Biotech was founded in 1999 as m-phasys by Dr. Hans Kiefer, Dr. Wolfgang Vogt, Marc Lohrmann and i.con. innovation GmbH.

Membrane proteins are the most commercially-interesting target proteins for medications and represent M-fold Biotech GmbH’s core area of expertise yet they are also the most difficult to work with. The key to the firm’s success was the use of the patented M-FOLD technology, which was used to manufacture membrane protein antigens. Using two very different methods (immunisation and “phage display” selection), the firm succeeded in manufacturing antibodies with the required binding properties and biological activity and selectivity.

In addition to structural analysis, m-phasys has recently established a new area of business, namely the manufacture of antibodies that act against membrane proteins and can themselves act as medications.

M-fold Biotech's customers include major pharmaceutical companies who commission the structural analyses in order to develop medications. 		12Structural explanations of therapeutically-relevant potassium channelsAssociated project: Joint project into the generation of antibodies against frizzled receptors (GPCRs) for the isolation and characterisation of stem cells.
4base lab GmbHBiotechServicesService provider in the field of genomics and proteomics; GMP analysesReutlingenDr. Despina Tougianidou
Dr. Thomas Maier
Dr. Manfred Bayer
1995Aspenhaustrasse 25
72770 Reutlingen
Germany
Tel.: +49 (0)7121-937557
Fax: +49 (0)7121-937558
Postal Adress:
Postfach 4023
72771 Reutlingen
Germany
info@4base-lab.dewww.4base-lab.de4base lab GmbH was founded in 1996 and provides services in the field of genome and proteome analysis. These include DNA sequencing, protein analysis (N-terminal sequencing, Edman degradation, MALDI-ToF analysis), the production of BAC and PAC clones, gene expression analysis, in vitro mutagenesis, mRNA 5’ mapping, polymerase chain reaction (PCR) analysis and cloning.
In the R&D sector, 4base lab primarily focuses on the development of assays for detecting viral pathogens. Quality assurance is carried out based on ISO 9001 standards for medical products, foodstuffs and life science consumables.

Drug testing involving DNA sequencing and real-time PCR is carried out in compliance with GMP standards.


4base lab GmbH has also developed the first CE-labelled test kit for the detection of all influenza A group viruses, which also includes the bird flu virus.
Birgit Blum (office@4base-lab.de)8The company holds the ISO 9001 certificate and is certified to carry out DNA sequencing and real-time PCR under GMP conditions. Development of assays for the detection of viral pathogens
PANATecs GmbHBiotechServices, Development, Medicine, Nutrigenomics, DiagnosticsProvision of bioanalytical services, particularly mass spectrometry-based, for the pharmaceutical, foodstuffs and animal feed industries. Manufacture and sale of bioanalytical substances for research (e.g. peptides, antibodies, marker reagents etc.).TübingenDr. Benedikt Merz,CEO
Dr. Thomas Flad, Pharmacist (CSO)
Alexander Cansier (COO)
2004Ob dem Himmelreich 7
72074 Tübingen
Germany
Tel.: +49 (0)7071-29720-93, -94 and -95
Fax: + 49 (0)7071-294445
info@panatecs.comwww.panatecs.comPANATecs GmbH was founded in 2004 as a spin-off of the University of Tübingen. Its founding partners are Prof. Claudia Müller (Transplantation Immunology and Immunohaematology Section, “Medizinische Klinik und Poliklinik”, Dept. II), Prof. Gerhard A. Müller (Nephrology & Rheumatology Department, Centre for Internal Medicine, Georg August University, Göttingen), Dr. Hubert Kalbacher (University of Tübingen, Physiological Chemistry Institute (PCI), Medical and Scientific Research Centre, University of Tübingen) and the two Managing Directors Dr. Thomas Flad and Alexander Cansier.

In addition to the production of bioanalytical products and the conducting of specialist analyses, PANATecs GmbH also carries out its own research projects. In collaboration with major partners, the firm handles projects from the field of clinical mass spectrometry. The aim of these research activities is to develop new, mass spectrometry-based diagnostic methods for the early detection of autoimmune and cancer-related diseases.
Alexander Cansier20ISO 9001 certified company
Manufacturing Authorization for Test Laboratories according to §13 of the German Medicines Act, including GMP certificate		Development of new tests for the molecular diagnosis of rheumatoid arthritis
Multi Channel Systems MCS GmbHBiotechDevelopment, Laboratory TechniquesElectrophysiology, automationReutlingenKarl-Heinz Boven (Managing Director)
Andreas Möller (Managing Director)
1996Aspenhaustrasse 21
72770 Reutlingen
Germany
Tel: +49 (0)7121-909250
Fax: +49 (0)7121-9092511
info@multichannelsystems.comwww.multichannelsystems.comMulti Channel Systems MCS GmbH was founded in 1996 and is based in the Reutlingen/Tübingen Science and Technology Park. Its focus lies on the development of measuring instruments and technical accessories in the context of electrophysiology for university-based research and the pharmaceutical industry. MCS products automate laborious measuring methods and analyses.

Three product lines demonstrate Multi Channel Systems’ core areas of expertise: in vitro and in vivo systems for the derivation of extracellular activities of excitable cells; the Robocyte, a fully-automatic “two-electrode voltage clamp (TEVC)” system for oocytes of the African clawed frog Xenopus laevis and its latest development, the QT Screen – an automated system for tests on the potential extension of the QT interval. This is a key instrument for safety pharmacology applications in the development of new medications.

The goal is always to develop intelligent and convenient solutions that combine maximum functionality with ease of use.		Karl-Heinz Boven16Development of a biotechnology platform for electrophysiological tissue assays for the investigation of active agents in conditions that are as similar as possible to in vivo